Valneva Shares Drop 3.19% Midday Ahead of Annual Results
Valneva is losing ground this Friday midday, continuing a negative week for the Nantes-based vaccine specialist's stock. The share price stands at 4.548 euros, down 3.19% from the previous day's close. The publication of the 2025 annual results, expected on March 16, is the next major milestone for the company.
Valneva shares are trading at 4.548 euros, showing a decline of 3.03% over the past seven days. However, this movement occurs within the context of a clearly positive medium-term trajectory, with the stock showing an increase of 19.06% over three months and nearly 39.5% over a year. Technically, the price still moves above its 50-day moving average, which is at 4.24 euros, indicating that the bullish trend remains intact at this stage. The RSI, at 59, reflects a balance zone, away from both overbought and oversold thresholds. The next resistance threshold is at 5.08 euros, while the most relevant support is at 3.89 euros, a level significantly lower than the current price.
Financial Calendar and Key Dates
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Valneva's financial calendar schedules the publication of the 2025 annual results for March 16, which is in ten days. This deadline is a crucial moment to assess the commercial and financial trajectory of the laboratory, particularly the evolution of its revenues from vaccines against chikungunya (Ixchiq) and Japanese encephalitis (Ixiaro). Subsequently, the results for the first quarter of 2026 are scheduled for May 7, and the general meeting will take place on June 1. It is worth noting that the stock has a beta of 0.26, indicating a low correlation with overall market movements, which reflects a profile specific to the company's own fundamentals rather than broad macroeconomic trends.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
